Masimo (MASI), Cleveland Clinic Unite to Enhance Patient Care
Barclays Maintains DaVita(DVA.US) With Hold Rating, Maintains Target Price $150
Barclays analyst Andrew Mok CFA maintains $DaVita(DVA.US)$ with a hold rating, and maintains the target price at $150.According to TipRanks data, the analyst has a success rate of 46.1% and a total av
BD's (BDX) New Research Tool to Aid Single-Cell Analysis
Glaukos (GKOS) Reaches 52-Week High: What's Driving the Stock?
DaVita HealthCare (DVA) Stock Slides as Market Rises: Facts to Know Before You Trade
Here's Why You Should Add Ecolab (ECL) to Your Portfolio Now
GE HealthCare's (GEHC) New Tie-Up to Boost CVD Workflow
Investors Met With Slowing Returns on Capital At DaVita (NYSE:DVA)
GE HealthCare (GEHC) Boosts Interventional Radiology Capabilities
Accuray (ARAY), TrueNorth Unite to Aid Radiation Departments
McKesson (MCK) Reaches 52-Week High: What's Aiding the Stock?
DexCom's (DXCM) G6 CGM System Combines With AID in Netherlands
DaVita HealthCare (DVA) Registers a Bigger Fall Than the Market: Important Facts to Note
Veeva's (VEEV) Vault EDC to Boost Vita Global's Data Management
McKesson (MCK) Introduces FDA-Approved Prostate Cancer Drug
Long-term Beneficiaries of AI, According to Goldman Sachs
Venus Concept's (VERO) Latest Supply Deal to Aid Its Business
GE HealthCare's (GEHC) New Tie-Up to Boost Patient Care in Mexico
Why DaVita HealthCare (DVA) Is a Top Growth Stock for the Long-Term
3 Reasons to Hold Veeva Systems (VEEV) Stock in Your Portfolio